167 related articles for article (PubMed ID: 15685823)
41. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
42. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.
Hirano A; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Okabe T; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
Anticancer Res; 2006; 26(1B):581-4. PubMed ID: 16739324
[TBL] [Abstract][Full Text] [Related]
43. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Conte PF; Donati S; Gennari A; Guarneri V; Orlandini C; Rondini M; Roncella M; Marini L; Collecchi P; Viacava P; Naccarato AG; Degli Esposti R; Bonardi S; Bottini A; Saracchini S; Tumolo S; Gullo G; Santoro A; Crino L
Br J Cancer; 2005 Aug; 93(4):406-11. PubMed ID: 16052214
[TBL] [Abstract][Full Text] [Related]
44. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Nieto Y; Aramendía JM; Espinós J; De la Cruz S; Fernández-Hidalgo O; Santisteban M; Arbea L; Aristu J; Martínez-Monge R; Moreno M; Pina L; Sola J; Zornoza G; Regueira FM
Cancer Chemother Pharmacol; 2010 Feb; 65(3):457-65. PubMed ID: 19526361
[TBL] [Abstract][Full Text] [Related]
45. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Steger GG; Greil R; Lang A; Rudas M; Fitzal F; Mlineritsch B; Hartmann BL; Bartsch R; Melbinger E; Hubalek M; Stoeger H; Dubsky P; Ressler S; Petzer AL; Singer CF; Muss C; Jakesz R; Gampenrieder SP; Zielinski CC; Fesl C; Gnant M;
Ann Oncol; 2014 Feb; 25(2):366-71. PubMed ID: 24347519
[TBL] [Abstract][Full Text] [Related]
46. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Fountzilas G; Nicolaides C; Bafaloukos D; Kalogera-Fountzila A; Kalofonos H; Samelis G; Aravantinos G; Pavlidis N
Cancer Invest; 2000; 18(6):503-9. PubMed ID: 10923097
[TBL] [Abstract][Full Text] [Related]
47. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
[TBL] [Abstract][Full Text] [Related]
48. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
49. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Díaz M; Miró C; Lobo F; Carrasco E; Casillas M; San Antonio B
Clin Transl Oncol; 2007 May; 9(5):317-22. PubMed ID: 17525042
[TBL] [Abstract][Full Text] [Related]
50. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
51. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Swain SM; Tang G; Geyer CE; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N
J Clin Oncol; 2013 Sep; 31(26):3197-204. PubMed ID: 23940225
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
53. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R
Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
55. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
56. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients.
Sánchez-Muñoz A; Dueñas-García R; Jaén-Morago A; Carrasco E; Chacón I; García-Tapiador AM; Ortega-Granados AL; Martínez-Ortega E; Ribelles N; Fernández-Navarro M; de la Torre-Cabrera C; Dueñas B; Rueda AI; Martínez J; Tortosa CR; Martín-Salvago MD; Sánchez-Rovira P
Am J Clin Oncol; 2010 Oct; 33(5):432-7. PubMed ID: 19952716
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
58. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant gemcitabine therapy for breast cancer.
Sánchez-Rovira P; Jaén A; Dueñas R; Porras I; Martínez E; Medina B; Mohedano N; Fernández M; Lozano A
Clin Breast Cancer; 2002 May; 3 Suppl 1():39-44. PubMed ID: 12057045
[TBL] [Abstract][Full Text] [Related]
60. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Jones RL; Walsh G; Ashley S; Chua S; Agarwal R; O'Brien M; Johnston S; Smith IE
Br J Cancer; 2009 Jan; 100(2):305-10. PubMed ID: 19165198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]